{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:32:44Z","timestamp":1793248364058,"version":"4.5.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent, potentially life-threatening episodes of bradykinin-mediated angioedema affecting the skin, gastrointestinal tract, and upper airway. Despite the availability of several prophylactic therapies, there is a need for effective and convenient treatment options. On 21 June 2024, the U.S. Food and Drug Administration approved Andembry\u2122 (garadacimab-gxii), a first-in-class monoclonal antibody that inhibits activated Factor XII (FXIIa), for prophylaxis of HAE attacks in patients aged \u226512\u00a0years. By targeting FXIIa, garadacimab acts upstream in the kallikrein\u2013kinin pathway, suppressing bradykinin generation and preventing vascular permeability associated with angioedema. Clinical trials demonstrated substantial reductions in attack frequency, with the phase 3 VANGUARD study reporting a 91.5% reduction in HAE attacks and that approximately 77% of patients remain attack-free during the study period. Garadacimab is administered as a 200-mg subcutaneous injection once monthly and has a favorable pharmacokinetic profile with an elimination half-life of approximately 18\u201320\u00a0days. Adverse events were generally mild, including headache, nasopharyngitis, and injection-site reactions. The approval of garadacimab represents an important advancement in HAE prophylaxis, offering a novel upstream mechanism, convenient dosing, and potential improvement in quality of life of the patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005029","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:00:48Z","timestamp":1780477248000},"page":"3924-3927","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Garadacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway"],"prefix":"10.1097","volume":"88","author":[{"given":"Harshika Khaim","family":"Chandani","sequence":"first","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Fadak Zahra","family":"Hujjat","sequence":"additional","affiliation":[{"name":"Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devya Khaim","family":"Chandani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College (SMBBMC), Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saad","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7907-3017","authenticated-orcid":false,"given":"Abubakr","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Khartoum, Khartoum State, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"R2-20261029","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R3-20261029","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/jcm10092023","article-title":"The genetics of hereditary angioedema: a review","volume":"10","author":"Santacroce","year":"2021","journal-title":"J Clin Med"},{"key":"R4-20261029","first-page":"e1010384","article-title":"SERPING1 mutations and HAE-nC1-INH variants: a genetics overview","volume":"19","author":"Smith","year":"2023","journal-title":"PLoS Genet"},{"key":"R5-20261029","first-page":"245\u201351","article-title":"Clinical features and mortality risk of laryngeal edema in HAE","volume":"182","author":"Thompson","year":"2022","journal-title":"JAMA Intern Med"},{"key":"R6-20261029","first-page":"23\u201330","article-title":"Long-term disease burden in hereditary angioedema: findings from the VANGUARD study","volume":"44","author":"Banerji","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"R7-20261029","first-page":"3175\u201388","article-title":"Diagnostic approach to HAE with normal C1-INH: consensus from HAE International","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"R8-20261029","first-page":"789\u201399","article-title":"Pharmacokinetics, pharmacodynamics, and safety of subcutaneous and intravenous garadacimab following single-dose administration in healthy Japanese and White adults","volume":"64","author":"Glassman","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"R9-20261029","first-page":"932\u201382","article-title":"Bradykinin receptor ligands: therapeutic perspectives","volume":"72","author":"Marceau","year":"2020","journal-title":"Pharmacol Rev"},{"key":"R10-20261029","doi-asserted-by":"crossref","first-page":"945\u201355","DOI":"10.1016\/S0140-6736(21)02225-X","article-title":"Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"399","author":"Craig","year":"2022","journal-title":"Lancet"},{"key":"R11-20261029","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/S2352-3026(24)00081-4","article-title":"Long-term efficacy, safety, and quality-of-life data from a phase 2 randomized, open-label extension trial of garadacimab for hereditary angioedema prophylaxis","volume":"11","author":"Craig","year":"2024","journal-title":"Lancet Haematol"},{"key":"R12-20261029","first-page":"12\u201321","article-title":"Garadacimab in hereditary angioedema: a randomized, double-blind, placebo-controlled Phase 3 study (VANGUARD)","volume":"390","author":"Zuraw","year":"2024","journal-title":"N Engl J Med"},{"key":"R13-20261029","first-page":"398\u2013404","article-title":"Health-related quality of life and patient-reported outcomes in hereditary angioedema","volume":"43","author":"Lumry","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"R14-20261029","first-page":"567\u201376","article-title":"FXIIa inhibitors in inflammatory and thrombotic conditions: beyond HAE","volume":"123","author":"Beuschlein","year":"2023","journal-title":"Thromb Haemost"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:01:10Z","timestamp":1793246470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005029","relation":{},"ISSN":["2049-0801","2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"},{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"2025-08-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}